Turmeric compound tested as sepsis treatment in new trial

NCT ID NCT07436130

Not yet recruiting Disease control Sponsor: Hospital Civil de Guadalajara Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether curcumin, the active compound in turmeric, can help regulate the overactive immune response in critically ill patients with sepsis. Fifty-six participants will receive either curcumin or a placebo alongside standard care for 10 days. Researchers will measure changes in inflammatory markers in the blood to see if curcumin can reduce harmful inflammation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: curcumin (a natural compound from turmeric)
What this could lead to: If it works, curcumin could become a low-cost addition to standard sepsis care, helping to control harmful inflammation and potentially improving recovery.
What could go wrong: This is a small, early-stage trial (56 people) testing only a blood marker, not survival or major outcomes. Curcumin may show no benefit or could interact with other treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEPSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Critical Illness infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEPSIS

Contacts and locations

Locations

Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde"

Guadalajara, Jalisco, 44280, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.